Enzon Expects First-Line Indication For Oncaspar In Mid-2006
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA accepts a supplemental BLA for the pediatric acute lymphoblastic leukemia therapy, the firm announces Dec. 1.
You may also be interested in...
Enzon Oncaspar Gains First-Line Leukemia Indication
Pegaspargase allows for a more convenient dosing regimen than Merck's Elspar, the current standard of care for acute lymphoblastic leukemia, FDA says.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.